达安基因(002030) - 2017 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 10.63% to CNY 18,387,086.01 year-on-year[8] - Operating revenue for the period was CNY 382,346,205.75, reflecting a growth of 3.92% compared to the same period last year[8] - The company reported a decrease of 23.83% in net profit after deducting non-recurring gains and losses, totaling CNY 13,753,387.99[8] - The basic earnings per share remained stable at CNY 0.03, with a year-to-date figure of CNY 0.11, down 8.33%[8] - The weighted average return on equity was 1.12%, a decrease of 0.36% compared to the same period last year[8] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 104.71% to CNY 12,139,848.98[8] - The net cash flow from operating activities was -¥148,272,884.62, an improvement of 65.92% compared to -¥435,050,188.30 in the previous year[21] - Total assets increased by 0.64% to CNY 4,166,111,721.97 compared to the end of the previous year[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 101,006[14] - The largest shareholder, Guangzhou Zhongda Holdings Co., Ltd., holds 16.63% of the shares, totaling 120,553,716 shares[14] - The company has not engaged in any repurchase transactions among its top shareholders during the reporting period[16] Government Support and Subsidies - The company received government subsidies amounting to CNY 28,105,819.86 during the reporting period[11] Receivables and Liabilities - The company's accounts receivable decreased by 41.42% to ¥576,858 from ¥984,680 due to the maturity of receivables[20] - Interest receivables increased by 325.89% to ¥4,878,766.65 from ¥1,145,555.56, attributed to accrued interest on term deposits[20] - The company’s total liabilities increased significantly, with other payables rising by 150.11% to ¥84,406,333.77 from ¥33,748,165.62[20] Investment and Financing Activities - Long-term borrowings increased by 77.43% to ¥354,850,000 from ¥200,000,000, indicating a rise in financing activities[20] - The company reported a 144.07% increase in investment income to ¥7,034,612.66 from ¥2,882,191.93, due to increased earnings from equity method investments[20] - The company plans to raise up to ¥1,500,000,000 through a non-public offering of shares to fund projects including the expansion of the fluorescent PCR product line and the construction of a research center[22] Other Business Income - The company’s other business income decreased by 65.88% to ¥1,291,487.59 from ¥3,784,936.56, primarily due to a reduction in leasing business[20]